Oxford Biomedica Regulatory News (OXB)

17 Mar 2008 12:32

Oxford Biomedica PLC17 March 2008 FOR IMMEDIATE RELEASE 17 MARCH 2008 OXFORD BIOMEDICA TO PRESENT AT COWEN AND COMPANY HEALTH CARE CONFERENCE Oxford, UK - 17 March 2008: Oxford BioMedica (LSE: OXB), a leading gene therapycompany, today announces that Nick Woolf, the Company's SVP Corporate Strategy,will give a presentation at the Cowen and Company 28th Annual Health CareConference on Tuesday, 18 March 2008, at 2.25PM EST (7.25PM BST). The conferenceis being held at the Boston Marriott Copley Place, MA. The presentation will be webcast live and may be accessed under the investorssection of the Company's website, www.oxfordbiomedica.co.uk. The presentationwill also be available for replay. -Ends- For further information, please contact: Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000 JPMorgan Cazenove Limited: James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828 City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000Communications Scientific/Trade Press Enquiries: Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 7457 2020 College Hill Life Sciences US Enquiries: Thomas Fechtner Tel: (646) 378 2900 The Trout Group LLC Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising incancer immunotherapy and gene-based therapies. The Company was established in1995, as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. The lead product candidate is TroVax(R),an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventisfor global development and commercialisation. TroVax is in Phase IIIdevelopment. Oxford BioMedica has three other products in clinical development,including ProSavin(R), a novel gene-based treatment for Parkinson's disease, ina Phase I/II trial. The Company is underpinned by over 80 patent families, whichrepresent one of the broadest patent estates in the field. The Company has astaff of approximately 85. Oxford BioMedica has collaborations withsanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licenseesinclude Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock Exchange